Drug intelligence / Profile preview

ODAM recombinant protein

Development stage
Preclinical
Lead developer
University of Tennessee
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous
01

Overview

ODAM recombinant protein is a recombinant form of the odontogenic ameloblast-associated protein (ODAM), also known as APIN. ODAM is a developmental antigen primarily involved in tooth maturation and the maintenance of junctional epithelium integrity. In oncology research, ODAM has been identified as a potential prognostic biomarker and therapeutic target, particularly in breast cancer and other epithelial malignancies. Ectopic expression or treatment with recombinant ODAM protein has been shown to moderate cell growth, increase apoptosis, and inhibit the migration and invasion of highly invasive breast cancer cells (such as MDA-MB-231) in vitro and in vivo, partially through modulating the TGF-beta signaling pathway and interacting with Runx2.

Other names
recombinant human ODAM proteinrecombinant human odontogenic ameloblast-associated proteinrecombinant ODAM
02

Targets

TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)BMPR1BHydroxyapatiteRUNX2

Beyond the preview

Go deeper on ODAM recombinant protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODAM recombinant protein.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call